Trial · NCT04103814
Effect of Topical CBD Cream for Degenerative Hallux Disorders
NCT04103814, Phase 2, Phase 3, Terminated, Rush University Medical Center; results first posted 2024-10-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Topical CBD Cream for Degenerative Hallux Disorders. Trials, record NCT04103814. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04103814
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Topical CBD Cream for Degenerative Hallux Disorders
- NCT number
- NCT04103814
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 11 participants, actual
- Lead sponsor
- Rush University Medical Center
- Conditions
- Hallux Valgus, Hallux Rigidus
- Interventions
- magnesium-cannabidiolic acid cream, Placebo cream
- First posted
- 2019-09-25
- Last updated
- 2024-10-15
- Results first posted
- 2024-10-15
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Post-treatment VAS Score Averaged Daily Over 4 Weeks. | 4 weeks | Weekly visual analog system (VAS) pain scores will be measured daily for four weeks. The VAS pain score is a measure of pain severity. It is measured on a scale from 0 to 10, with 10 being the worst pain the patient has experienced. No patients completed full enrollment so no data was analyzed. |
| Primary | Weekly Foot Function Index | 4 weeks | The foot function index (FFI) is a questionnaire that measures foot pain and disability. It is self-administered and consists of 23 items divided into 3 subscales (pain, disability, and activity limitation). The pain subcategory consists of 9 questions (scored out of 90) and is a measure of pain in different situations, such as walking with shoes versus barefoot. The disability subcategory consists of 9 questions (scored out of 90) and measures functional activities, such as difficulty walking upstairs. The activity limitation subcategory consists of 5 questions (scored out of 50) and measures limitations caused by the foot problem. All three subcategories are summed together to get a final number, with higher numbers indicating worse pain. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Post-treatment VAS Score Averaged Daily Over 4 Weeks. | 4 weeks | No data were analyzed for this outcome because there were no participants data collected. | ||
| PRIMARY | Weekly Foot Function Index | 4 weeks | No data were analyzed for this outcome because there were no participants data collected |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | CBD Cream | 8 | |
| Overall Study | STARTED | Control | 3 | |
| Overall Study | COMPLETED | CBD Cream | 0 | |
| Overall Study | COMPLETED | Control | 0 | |
| Overall Study | NOT COMPLETED | CBD Cream | 8 | |
| Overall Study | NOT COMPLETED | Control | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mg-CBDa Cream | 0 | 11 |
| Total, all-cause mortality | Placebo Cream | 0 | 11 |
| Total, other adverse events | Mg-CBDa Cream | 0 | 11 |
| Total, other adverse events | Placebo Cream | 0 | 11 |
| Total, serious adverse events | Mg-CBDa Cream | 0 | 11 |
| Total, serious adverse events | Placebo Cream | 0 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Mg-CBDa Cream vs Placebo Cream: deaths from any cause | Trial comparisons |
| Mg-CBDa Cream vs Placebo Cream: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04103814
GET https://conductscience.org/api/trials/v1/NCT04103814/registered